Atlas Capital Advisors Inc. Takes $63,000 Position in Solventum Co. (NYSE:SOLV)

Atlas Capital Advisors Inc. bought a new position in Solventum Co. (NYSE:SOLV) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 950 shares of the company’s stock, valued at approximately $63,000.

A number of other institutional investors have also bought and sold shares of the business. Worldquant Millennium Advisors LLC boosted its stake in shares of Solventum by 373.6% in the third quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock worth $3,323,000 after acquiring an additional 37,600 shares during the period. Harbor Capital Advisors Inc. lifted its holdings in Solventum by 24.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock worth $3,103,000 after purchasing an additional 9,333 shares in the last quarter. State Street Corp boosted its stake in Solventum by 3.1% in the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after purchasing an additional 185,938 shares during the period. Forsta AP Fonden purchased a new stake in Solventum during the 4th quarter valued at approximately $1,876,000. Finally, New York State Teachers Retirement System raised its position in shares of Solventum by 4.0% during the fourth quarter. New York State Teachers Retirement System now owns 124,699 shares of the company’s stock valued at $8,238,000 after buying an additional 4,819 shares during the last quarter.

Solventum Stock Performance

Solventum stock opened at $66.22 on Friday. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92. The company’s 50-day moving average is $75.42 and its 200 day moving average is $71.95. The firm has a market capitalization of $11.45 billion and a P/E ratio of 24.08. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SOLV shares. Mizuho raised their target price on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Wells Fargo & Company increased their target price on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Morgan Stanley upped their target price on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 5th. Bank of America lifted their price target on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. Finally, Piper Sandler upped their price objective on Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Solventum currently has a consensus rating of “Hold” and a consensus price target of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.